Abstract:The emergence of the new coronavirus (nCoV-19) has impacted human health on a global scale, while the interaction between the virus and the host is the foundation of the disease. The viral genome codes a cluster of proteins, each with a unique function in the event of host invasion or viral development. Under the current adverse situation, we employ virtual screening tools in searching for drugs and natural products which have been already deposited in DrugBank in an attempt to accelerate the drug discovery process. This study provides an initial evaluation of current drug candidates from various reports using our systemic in silico drug screening based on structures of viral proteins and human ACE2 receptor. Additionally, we have built an interactive online platform (<a class="extLink" href="https://shennongproject.ai/">https://shennongproject.ai/</a>) for browsing these results with the visual display of a small molecule docked on its potential target protein, without installing any specialized structural software. With continuous maintenance and incorporation of data from laboratory work, it may serve not only as the assessment tool for the new drug discovery but also an educational web site for the public.This article has not yet been cited by other publications.

What problem does this paper attempt to address?

This paper aims to solve the problem of drug discovery for coronavirus disease (COVID - 19) caused by the novel coronavirus (SARS - CoV - 2). Specifically, the research team uses virtual screening methods to search for small - molecule compounds that can bind to key proteins of the novel coronavirus or the human ACE2 receptor from known drug libraries, so as to accelerate the drug discovery process. The main contributions of the paper include: 1. **Virtual Screening**: The research team used 8,506 compounds from DrugBank to conduct virtual screening against some druggable proteins of the novel coronavirus and the human ACE2 receptor, generating more than 18,000 docking results. 2. **Online Interactive Platform**: In order to facilitate scientific researchers and the public to access these screening results, the research team built an online interactive platform named "Shennong Project" (https://shennongproject.com). Users can browse the docking situation between small molecules and potential target proteins through this platform without installing professional structural software. 3. **Preliminary Evaluation**: Based on the results of virtual screening, the research team conducted a preliminary evaluation of some currently reported drug candidates, providing an analysis of the binding ability of these drugs at the structural level. 4. **Education and Popular Science**: In addition to being a tool for drug discovery, this platform also has an educational function and can popularize relevant knowledge of the novel coronavirus to the public. ### Specific Problems Solved by the Paper 1. **Accelerate Drug Discovery**: Through virtual screening, quickly identify existing drugs that may be effective against the novel coronavirus, thereby speeding up the drug development process. 2. **Provide Data Resources**: Make the screening results public through an online platform, facilitating other researchers to further verify and utilize these data. 3. **Improve Transparency and Accessibility**: Through a user - friendly interface, enable non - professional users to understand and use these complex bioinformatics data. ### Main Research Methods - **Virtual Screening**: Use molecular docking technology to evaluate the binding affinity between small molecules and target proteins. - **Structural Prediction**: For proteins with no known structure, predict their three - dimensional structure through homology - modeling methods. - **Online Platform Development**: Build an interactive web page to display screening results and detailed docking models. ### Overview of Results - **High - Affinity Drugs**: Some antiviral drugs such as Saquinavir, Lopinavir, Darunavir, etc. showed high binding affinity in the screening. - **Natural Products**: Some natural products such as Quinine also showed a certain inhibitory effect. - **Clinical Trial Drugs**: Drugs such as Remdesivir and Lopinavir, which have already shown good effects in clinical trials, have also been verified in virtual screening. ### Conclusion This research provides a fast and effective solution for drug discovery of the novel coronavirus through virtual screening and the construction of an online platform, and provides valuable data resources and tools for future drug development.

Systemic In Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server

Bioinformatics resources facilitate understanding and harnessing clinical research of SARS-CoV-2.

OverCOVID: an Integrative Web Portal for SARS-CoV-2 Bioinformatics Resources

Structure-based Virtual Screening, in Silico Docking, ADME Properties Prediction and Molecular Dynamics Studies for the Identification of Potential Inhibitors Against SARS-CoV-2 Mpro.

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Virus-CKB: an integrated bioinformatics platform and analysis resource for COVID-19 research

In silico virtual screening, characterization, docking and molecular dynamics studies of crucial SARS-CoV-2 proteins

Identification of Therapeutic Drugs Against COVID-19 Through Computational Investigation on Drug Repurposing and Structural Modification

Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing

Ligand-based approach for predicting drug targets and for virtual screening against COVID-19

Structure-Based Virtual Screening and Identification of Potential Inhibitors of SARS-CoV-2 S-RBD and ACE2 Interaction

Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment

A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism

In silico discovery of multi-targeting inhibitors for the COVID-19 treatment by molecular docking, molecular dynamics simulation studies, and ADMET predictions

In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs

In silico Drug Repurposing for COVID‐19: Targeting SARS‐CoV‐2 Proteins through Docking and Consensus Ranking

Identification of potential antiviral compounds against SARS-CoV-2 structural and non structural protein targets: A pharmacoinformatics study of the CAS COVID-19 dataset

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

In-Silico Screening and Molecular Dynamics Simulation of Drug Bank Experimental Compounds against SARS-CoV-2

Target-Based in Silico Screening for Phytoactive Compounds Targeting SARS-CoV-2

Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2